Pancreatic cancer will become the second-leading cause of death in the U.S. by 2030. About 10% to 15% of those pancreatic cancers originate from cysts. While it sounds ominous, “it’s something that we can actually intervene upon before it has the opportunity to turn into cancer,” according to Christopher Chapman, MD, a gastroenterologist with Rush University System for Health in Chicago.
Pancreatic cysts are extremely common but often cause anxiety for patients. Standard treatment usually involves surveillance imaging such as MRIs or CT scans, endoscopic procedures, or more invasive surgery.
Rush is one of the few hospitals in the country and the only facility in Illinois that has been pioneering a chemoablation method for treating pancreatic cysts that pose a cancer risk. Under this procedure, physicians use endoscopic ultrasound to place a fine needle directly into the cyst to inject targeted chemotherapy.
“Initially the words ‘chemo’ make patients feel unsettled, but because only a small volume is placed directly into the cyst, there is no additional risk for the significant side effects that people typically think of. Due to its safety and effectiveness, we felt that patients in the Chicagoland area and in the Midwest in general should have the opportunity to access this novel approach close to home,” said Dr. Chapman, who joined Rush gastroenterologist Neal Mehta, MD for an interview with the AMA about the procedure.
As part of the Center for Therapeutic and Interventional Endoscopy (CITE) at Rush University, Drs. Chapman and Mehta share a passion for innovation.
“We enjoy doing procedures, but our passion is innovation,” said Dr. Chapman. “If there is an opportunity to improve our patient’s lives using a minimally invasive endoscope instead of going under a scalpel, we will pursue it.”
“Chemoablation is exciting because it has the capacity to shrink a large-sized cyst down to the point where it’s undetectable on an MRI. Instead of just performing surveillance scans and waiting for something high risk to show up, this treatment offers a chance for therapy before the cysts turn into cancer, offering patients a chance for prevention,” he said.
Rush University System for Health is part of the AMA Health System Member Program, which provides enterprise solutions to equip leadership, physicians and care teams with resources to help drive the future of medicine.
Adoption called for buy-in, training across disciplines
Many people are getting incidentally diagnosed with pancreatic cysts, especially in large metropolitan areas.
“It’s an issue that puts strain on the healthcare system as multiple surveillance MRIs start to add up in quantity, cost, and mental anxiety for the patient,” said Dr. Mehta.
Matthew Moyer, MD at Penn State Health, is one of the lead physicians who developed this chemoablation method and “utilizing his protocol, we wanted to bring this therapeutic option to our patients here in Illinois,” Dr. Mehta explained.
This called for buy-in from many stakeholders across Rush University System for Health. Under this multidisciplinary approach, Rush’s surgeons, its pharmacy and the nursing staff all needed training for instilling chemotherapeutic drugs. It also meant having the appropriate disposal products to handle this chemotherapeutic drug.
“You can’t be doing this on an island alone,” said Dr. Mehta.
Surgical oncologists, who play a huge part in the management of these pancreatic cysts, were an important component of this program.
The first step in ablation involves endoscopic ultrasound. Not everyone is trained in this—it requires an additional year in a fellowship training to master endoscopic ultrasound, said Dr. Mehta. Then there’s the triaging of these cysts—knowing which ones to watch and knowing which ones to ablate.
“Just because we can ablate everything doesn’t mean we should, or just because we should watch everything doesn’t mean we should,” he emphasized.
Cysts either fall into a high-risk category, which requires surgical intervention, or low risk, which involves surveillance.
“But all these cysts aren’t white or black,” said Dr. Mehta. “They fall into this gray area sometimes, such as high-risk cysts in nonsurgical patients, for example.”
Dr. Chapman added that there are certain cysts that may not respond well if they develop a mass or nodule inside.
“That means it’s just too advanced for the treatment to be effective and we need to catch and intervene on these cysts before they progress,” he said.
Learning the cadence of what is important to look at, what features are high-risk versus which are low risk, is important, and “we get that training over time,” said Dr. Mehta.
Team conferences chart treatment plans
Rush leverages this multidisciplinary setting to discuss the best course of action for patients. Is it surgery or chemoablation? Or is the best option surveillance in some cases? Dr. Mehta explained.
A team of surgeons and gastroenterologists meet once a month to discuss these high-risk cysts and plan things face-to-face.
“It’s not over chats, messages or virtual meetings,” he said. “We come and sit down, review the images together and come up with a plan that’s personalized for the patient, to see what is best for them.”
Having surgeons review the images together and getting that buy-in is unique to Rush, Dr. Mehta added. It’s also important to do molecular testing to ensure you have the right cyst that’s appropriate for treatment.
And then there’s the long-term surveillance team and protocol, “so even though we hope and expect people to respond to the treatment with cyst eradication, we still have to keep an eye on them to make sure that we’re making the progress we expected,” said Dr. Chapman.
Dr. Mehta added that radiologists do routine surveillance scans and see what these changes look like post-ablation.
Proactive intervention eliminates the “watch and wait”
Rush, which has been doing this procedure for more than a year now, offers new hope to patients anxious about pancreatic cysts, Dr. Chapman said.
“The alternative is surgery for a lot of these people. A lot of times they may have other medical health issues that may prevent them from getting definitive surgery,” he noted. “Or some people just feel that surgery is too invasive for what they want.”
What’s unique about chemoablation is it offers a solution, rather than just saying, “Let’s just watch and wait and hope for nothing bad to happen,” said Dr. Chapman. “Now we can actually try to intervene and try to break that cycle before it has the chance to become cancer.”
The results thus far have been remarkable: the CITE team has treated cysts ranging from 3 to 11 centimeters. The 11-centimeter cyst appeared in a patient who was not a surgical candidate. It has since shrunk to less than 3 centimeters. Through this procedure, you reduce the risk tremendously of the cyst developing into cancer, noted Dr. Mehta.
Telling someone they have a precancerous lesion or a cyst keeps them up at night. Being able to intervene on this is helpful, said Dr. Mehta, adding, “We’re really happy to see this program take off.”
A center of excellence for the pancreas
Rush is currently an approved National Pancreas Foundation Center of Excellence recognized not only for pancreatic cysts, but also the multidisciplinary, patient centered approach for the treatment of acute pancreatitis, chronic pancreatitis and pancreatic cancer.
“We just want to spread awareness that it is available,” said Dr. Mehta. “As more people hear about it, we hope to provide this to not just the people in the greater Chicago area, but around the Midwest as well.”
“As we continue to grow this program and treat high-risk cysts that are referred to us, we hope to become leaders of this treatment in the Midwest, follow these patients long-term, and study our outcomes longitudinally,” he said.